Listed

Sutro Biopharma, Inc.

STRONasdaqCIK 1382101HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$9.8mRevenue, Q2 FY2026, three months to 2026-06-30$9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 12, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$9.8mRevenue, Q2 FY2026, three months to 2026-06-30$9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure−84.6% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−303.8%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$29.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Revenue: $9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure−298.5 pts on a year earlier
  • Net margin−391.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$38.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Revenue: $9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure−373.6 pts on a year earlier
  • Diluted EPS−$2.33Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure−72.6% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$9.8mOperating margin −303.8%
Diluted EPS−$2.33, Q2 FY2026
Sutro Biopharma, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m8.5Revenue, Q3 FY2024, three months to 2024-09-30$8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Report this figure14.8Revenue, Q4 FY2024, three months to 2024-12-31$14.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Report this figure17.4Revenue, Q1 FY2025, three months to 2025-03-31$17.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Report this figure63.7Revenue, Q2 FY2025, three months to 2025-06-30$63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure9.7Revenue, Q3 FY2025, three months to 2025-09-30$9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Report this figure11.6Revenue, Q4 FY2025, three months to 2025-12-31$11.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Report this figure14.5Revenue, Q1 FY2026, three months to 2026-03-31$14.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Report this figure9.8Revenue, Q2 FY2026, three months to 2026-06-30$9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(797.2%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$67.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Revenue: $8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Report this figure(440.7%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$65.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Revenue: $14.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Report this figure(393.8%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$68.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Revenue: $17.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Report this figure(5.2%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Revenue: $63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure(499.9%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$48.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Revenue: $9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Report this figure(326.7%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$38.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Revenue: $11.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Report this figure(204.2%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$29.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Revenue: $14.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Report this figure(303.8%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$29.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Revenue: $9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure
Net margin%(572.6%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$48.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Revenue: $8.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Report this figure(489.2%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$72.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Revenue: $14.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Report this figure(436.6%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$76.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Revenue: $17.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Report this figure(18.0%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$11.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Revenue: $63.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure(586.6%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$56.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Revenue: $9.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Report this figure(401.5%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$46.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Revenue: $11.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873. Derived: 12-month figure less the 9-month figure.Report this figure(265.0%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$38.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Revenue: $14.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Report this figure(391.6%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$38.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Revenue: $9.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure
Diluted EPS$ per share(0.59)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Report this figurenot reported (Diluted EPS not reported)(9.08)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$9.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Report this figure(1.35)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure(0.67)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-270036.Report this figurenot reported (Diluted EPS not reported)(2.94)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$2.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001193125-26-224170.Report this figure(2.33)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345748.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$102.5mOperating margin −154.5%
Diluted EPS−$22.49, FY2025
Sutro Biopharma, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m61.9Revenue, FY2021, twelve months to 2021-12-31$61.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-25, accession 0000950170-24-035949.Report this figure67.8Revenue, FY2022, twelve months to 2022-12-31$67.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0000950170-25-038884.Report this figure154Revenue, FY2023, twelve months to 2023-12-31$153.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0000950170-25-038884.Report this figure62.0Revenue, FY2024, twelve months to 2024-12-31$62.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873.Report this figure102Revenue, FY2025, twelve months to 2025-12-31$102.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(159.2%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$98.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-25, accession 0000950170-24-035949.Revenue: $61.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-25, accession 0000950170-24-035949.Report this figure(190.3%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$128.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-13, accession 0000950170-25-038884.Revenue: $67.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0000950170-25-038884.Report this figure(58.1%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$89.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-13, accession 0000950170-25-038884.Revenue: $153.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0000950170-25-038884.Report this figure(384.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$238.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001193125-26-119873.Revenue: $62.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873.Report this figure(154.5%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$158.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-23, accession 0001193125-26-119873.Revenue: $102.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873.Report this figure
Net margin%(170.6%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$105.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-25, accession 0000950170-24-035949.Revenue: $61.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-25, accession 0000950170-24-035949.Report this figure(175.9%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$119.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0000950170-25-038884.Revenue: $67.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0000950170-25-038884.Report this figure(69.5%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$106.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0000950170-25-038884.Revenue: $153.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0000950170-25-038884.Report this figure(366.6%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$227.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001193125-26-119873.Revenue: $62.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873.Report this figure(186.5%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$191.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-23, accession 0001193125-26-119873.Revenue: $102.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119873.Report this figure
Diluted EPS$ per share(2.29)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-25, accession 0000950170-24-035949.Report this figure(2.35)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-13, accession 0000950170-25-038884.Report this figure(1.78)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-13, accession 0000950170-25-038884.Report this figure(29.40)Diluted EPS, FY2024, twelve months to 2024-12-31−$29.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-23, accession 0001193125-26-119873.Report this figure(22.49)Diluted EPS, FY2025, twelve months to 2025-12-31−$22.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-23, accession 0001193125-26-119873.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Sutro Biopharma, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
PERCEPTIVE ADVISORS LLC2026-06-30$43.3m1,304,846Added+589,539
BVF INC/IL2026-06-30$41.6m1,251,788Unchanged
Affinity Asset Advisors, LLC2026-06-30$38.9m1,172,487Added+102,968
BlackRock, Inc.2026-06-30$37.3m1,122,655Added+889,971
SAMSARA BIOCAPITAL, LLC2026-06-30$35.3m1,062,872Unchanged
Kynam Capital Management, LP2026-06-30$29.0m872,558Unchanged
ORBIMED ADVISORS LLC2026-06-30$24.7m743,944Reduced−57,200
Balyasny Asset Management L.P.2026-06-30$23.6m711,162Added+245,370
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$23.0m694,219Reduced−26,223
EVENTIDE ASSET MANAGEMENT, LLC2026-06-30$19.4m585,262Reduced−130,045

Recent filings

All 611 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Sutro Biopharma, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-1207:30 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-345748
2026-08-1207:15 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-345733
2026-06-0816:01 ET8-K5.07 Shareholder vote results0001193125-26-261658
2026-05-1416:30 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-224170
2026-05-1416:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-224065
2026-04-2216:05 ETDEF 14AProxy statementPeriod 2026-06-050001193125-26-170354
2026-03-2316:44 ET10-KAnnual reportPeriod 2025-12-310001193125-26-119873
2026-03-2316:32 ET8-K1.02 Termination of a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-119844
2026-02-1017:16 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-044934
2025-12-1716:38 ET8-K8.01 Other events0001193125-25-322859

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 23, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1382101
Tickers
STRO
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
not reported
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
SUTRO BIOPHARMA INC (to 2018-11-08); Fundamental Applied Biology Inc (to 2007-10-24)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.